DALLAS, Jan. 12, 2010 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring biopharmaceutical company Achillion Pharmaceuticals Inc. (Nasdaq:ACHN). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.stockpreacher.com/n/ACHN
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
Achillion Pharmaceuticals Inc. (ACHN) is pharmaceutical company which engages in the discovery, development and commercialization of innovative treatment for infectious diseases. The Company focuses on the development of antivirals for the treatment of chronic hepatitis and the development of antibacterials for the treatment of resistant bacterial infections. As of December 31, 2008, ACHN focused its activities on advancing two late-stage preclinical candidates: ACH-1095, an NS4A antagonist for the treatment of chronic hepatitis C, being developed in collaboration with Gilead Sciences Inc. (Gilead), and ACH-1625, a protease inhibitor also for the treatment of chronic hepatitis C. In addition, the Company has a pipeline of other product candidates, which include elvucitabine for the treatment of HIV infection and ACH-702 for the treatment of serious bacterial infections.
Message Board Search for ACHN: http://www.boardcentral.com/boards/ACHN
In the report, the analyst notes:
"On Monday, the Company announced additional positive preliminary data from its clinical trial of ACH-1625 hepatitis-C treatment, boosting its shares in pre-market trade. The Company reported that 'Preliminary results showed that a mean reduction in viral load of 4.25 log10 was achieved in the treatment group, as compared to a mean reduction of 0.29 log10 in the placebo group...'"
"Commenting on the positive news, ACHN president and CEO stated, 'These compelling interim results are very encouraging as we continue to advance the clinical development of this compound for the treatment of HCV. Not only are the results especially robust, but they give us proof-of-concept ahead of schedule. This is a credit to our top-notch research and development team, which deserves recognition for its scientific excellence and tireless efforts.'"
To read the entire report visit: http://www.stockpreacher.com/n/ACHN
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.